Treatment Decision-Making for Leptomeningeal Metastasis After TKI Resistance in EGFR-Mutant Lung Cancer: A Comprehensive Review on Staging, Resistance Patterns, and Multimodal Interventions - Takeaways - MDSpire

Treatment Decision-Making for Leptomeningeal Metastasis After TKI Resistance in EGFR-Mutant Lung Cancer: A Comprehensive Review on Staging, Resistance Patterns, and Multimodal Interventions

  • By

  • Song, Guo-qiang

  • He, Tian Li

  • Ji, Ke-jie

  • Duan, Yi-meng

  • Hu, Guo-qiang

  • April 30, 2026

  • 0 min

Share

  • 1

    Leptomeningeal metastasis is a severe complication in EGFR-mutant NSCLC patients with TKI resistance.

  • 2

    Management of LM is complicated by tumor staging heterogeneity and diverse resistance mechanisms.

  • 3

    Current treatment strategies for LM lack standardization and require personalized clinical decision-making.

  • 4

    Multimodal approaches, including targeted therapies and intrathecal drug administration, can enhance outcomes.

  • 5

    Future improvements in drug resistance identification and CNS drug delivery are essential for better patient prognosis.

Original Source(s)

Treatment Decision-Making for Leptomeningeal Metastasis After TKI Resistance in EGFR-Mutant Lung Cancer: A Comprehensive Review on Staging, Resistance Patterns, and Multimodal Interventions

  • by Song, Guo-qiang , He, Tian Li , Ji, Ke-jie , Duan, Yi-meng , Hu, Guo-qiang

  • April 30, 2026

Related Content

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications

Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and